Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in Infants and Young Children With Hypochondroplasia
NCT07126262Phase 2Recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Peptides
- Countries
- 7
01
Overview
A Phase 2 trial of vosoritide in hypochondroplasia (HCH), sponsored by BioMarin Pharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
vosoritide
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on NCT07126262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126262.